Category: Regulatory DisclosuresBy adminMarch 25, 2021 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:EGX disclosure regarding the upcoming EGM/OGM on 18 April 2021NextNext post:Disclosure to EGX correcting the number of BoD meetings in the Annual BoD ReportRelated PostsRameda Announces New Chairman and Additions to its Board of DirectorsJune 3, 2026Rameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025BOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024
